This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: September 6, 2005
Last updated: May 9, 2011
Last verified: May 2011
Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan

Condition Intervention Phase
Infections, Nosocomial Drug: linezolid Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Linezolid (PNU-10766/PNU10766SS) in the Treatment of MRSA Infections in Patients Whose Conventional Therapy Has Failed, or Who Are Intolerant to Conventional Therapy; an Open-label, Multi-center Trial

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Resolution of infection at the time of completion of therapy

Secondary Outcome Measures:
  • Adverse events

Enrollment: 24
Study Start Date: January 2003
Study Completion Date: January 2006

Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • infection due to methicillin-resistant Staphylococcus aureus

Exclusion Criteria:

  • hypersensitivity to linezolid
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00150332

Pfizer Investigational Site
Kamogawa, Chiba, Japan, 296-0041
Pfizer Investigational Site
Onga-gun, Fukuoka, Japan, 807-0051
Pfizer Investigational Site
Sappopro, Hokkaido, Japan, 060-8648
Pfizer Investigational Site
Sapporo, Hokkaido, Japan, 006-8555
Pfizer Investigational Site
Moriya, Ibaraki, Japan, 302-0118
Pfizer Investigational Site
Yokohama, Kanagawa, Japan, 236-0051
Pfizer Investigational Site
Isahaya, Nagasaki, Japan, 854-8501
Pfizer Investigational Site
Kurashiki, Okayama, Japan, 701-0912
Pfizer Investigational Site
Kurashiki, Okayama, Japan
Pfizer Investigational Site
Suita, Osaka, Japan, 565-8565
Pfizer Investigational Site
Iruma-gun, Saitama, Japan, 350-0495
Pfizer Investigational Site
Kodaira, Tokyo, Japan, 187-0004
Pfizer Investigational Site
Fukuoka, Japan, 811-0213
Pfizer Investigational Site
Fukuoka, Japan, 813-0025
Pfizer Investigational Site
Hiroshima, Japan, 730-8619
Pfizer Investigational Site
Hiroshima, Japan, 734-8530
Pfizer Investigational Site
Kyoto, Japan, 615-8256
Pfizer Investigational Site
Nagasaki, Japan, 852-8501
Pfizer Investigational Site
Okayama, Japan, 700-8505
Pfizer Investigational Site
Okayama, Japan, 703-8275
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer Identifier: NCT00150332     History of Changes
Other Study ID Numbers: M12600067
Study First Received: September 6, 2005
Last Updated: May 9, 2011

Additional relevant MeSH terms:
Communicable Diseases
Cross Infection
Iatrogenic Disease
Disease Attributes
Pathologic Processes
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 21, 2017